PubMed Health⌕ Search

Biomedical subjects

D Hefner

Publications and source records attributed to D Hefner.

2 recordsLinked to original sources

Cyclic AMP modulates fast axonal transport in Aplysia bag cell neurons by increasing the probability of single organelle movement.

Stimulation of Aplysia bag cell neurons triggers elevation of cAMP and prolonged secretion of ELH neuropeptide. Using video-enhanced microscopy to track individual organelle movements in bag cell neurons, we find that organelle translocation consists of periods of movement interrupted by stationary episodes. cAMP elevation leads to a 2- to 3-fold enhancement of the average rate of organelle transport in both anterograde and retrograde directions. This effect does not result from alteration of the instantaneous velocity of organelle transport along microtubules, but rather from an increase in the proportion of time individual organelles spend in motion. Biochemical measurements also provided evidence that cAMP elevation promotes ELH peptide translocation from the somata into axons. Enhanced transport of ELH as a result of these effects may contribute to the replenishment of neuropeptide-containing vesicles at release sites during prolonged periods of secretion.

Animals↗

Evaluation of the maximum allowable cost program.

This article summarizes an evaluation of the Maximum Allowable Cost (MAC)-Estimated Acquisition Cost (EAC) program, the Federal Government's cost-containment program for prescription drugs. The MAC-EAC regulations which became effective on August 26, 1976, have four major components: (1) Maximum Allowable Cost reimbursement limits for selected multisource or generically available drugs; (2) Estimated Acquisition Cost reimbursement limits for all drugs; (3) "usual and customary" reimbursement limits for all drugs; and (4) a directive that professional fee studies be performed by each State. The study examines the benefits and costs of the MAC reimbursement limits for 15 dosage forms of five multisource drugs and EAC reimbursement limits for all drugs for five selected States as of 1979.

Cost-Benefit Analysis↗